Ru(II)-phytocompound complexes: a rational strategy to obtain potential metallopharmaceuticals

Abstract

Cancer is one of the most deadly diseases in the world, in addition to being always growing, both in number and in diversity. Thus, in view of the need for more efficient drugs than those found on the market, and with fewer side effects than those presented by the drugs used in the treatment of the disease, the development of organic or inorganic anticancer agents, in order to find new drug candidates for Cancer treatment has gained increasing importance in the scientific field. For this, several transition metals have been used, seeking to identify more selective and effective compounds, without side effects. In particular, ruthenium-based compounds have shown promising cytotoxic properties, which has encouraged many research groups to develop studies focused on this metal. In this context, the present work plan consists in the investigation of the antitumor potential of ruthenium complexes, through in vitro and in vivo assays, being an integral part of our thematic project "X-ray diffraction as a tool in potential drug development" (2017/15850-0). (AU)